CNCE Concert Pharmaceuticals Inc

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

A webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005071/en/

Justine Koenigsberg (781) 674-5284 ir@concertpharma.com

Grafico Azioni Concert Pharmaceuticals (NASDAQ:CNCE)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni Concert Pharmaceuticals (NASDAQ:CNCE)
Storico
Da Mag 2023 a Mag 2024